Skip to main content

Table 2 Adverse Event of dacomitinib and afatinib

From: The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study

  

Dacomitinib (n = 31)

Afatinib (n = 70)

p-value

Skin Rash/ Acne

   

0.376

    Grade1–2

83 (82.2)

25 (80.6)

58 (82.9)

 

    Grade > 2

3 (3.0)

0 (0)

3 (4.3)

 

Stomatitis/oral ulcer

   

0.547

    Grade1–2

42 (41.6)

15 (48.4)

27 (38.6)

 

    Grade > 2

1 (1.0)

0 (0)

1 (1.4)

 

Diarrhea

   

< 0.001

    Grade1–2

62 (61.4)

11 (35.5)

51 (72.9)

 

    Grade > 2

2(2.0)

0(0)

2(2.9)

 

Paronychia

   

0.004

    Grade 1–2

27 (26.7)

15 (48.4)

12 (17.1)

 

    Grade > 2

13 (14.3)

3 (9.7)

10 (14.3)

 

Pruritus

   

0.141

    Grade 1–2

72 (71.3)

19 (61.3)

53 (75.7)

 

    Grade > 2

0 (0)

0 (0)

0 (0)

 
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us